On May 15th, two members of a panel of doctors cast doubt on a Food and Drug Administration (FDA) advisory recommendation issued in March against testosterone replacement therapy (TRT) for hypogonadism. Medpage Today reports that two prominent endocrinologists are critical of the FDA’s decision, considering it premature. Dr. Sandeep Dhindsa, MD, of the Texas Tech…